IncontiLase® is a patent-pending, non-invasive Er:YAG laser therapy for the treatment of mild and moderate stress urinary incontinence, based on non-ablative photothermal stimulation of collagen neogenesis, shrinking and tightening of vaginal mucosa tissue and collagen-rich endopelvic fascia, and subsequently greater support to the bladder.

The indications for IncontiLase therapy are mild and moderate stress- and mixed urinary incontinence (SUI). Preliminary clinical studies show that it is an efficient, easy-to-perform and safe procedure.

Fotona’s 2940 nm Er: YAG non-ablative laser with proprietary “Smooth-mode” technology thermally affects the vaginal tissue, stimulating collagen remodelling and the synthesis of new collagen fibres in the region of the vestibule and urethral orifice, as well as in the area along the anterior vaginal wall. The final result of collagen neogenesis is the shrinking and tightening of vaginal mucosa tissue and collagen-rich endopelvic fascia and subsequently greater support to the bladder and the return of normal continence function.

For a large majority of patients, a single session was sufficient to alleviate mild or even moderate stress urinary incontinence. If needed, the treatment was repeated after one month. No special pre-op preparations or post-op precautions were necessary. Patients could immediately return to their normal everyday activities. Additional advantages objective Q-tip and PFM measurements. 90% of patients with mild SUI and 76% of patients with moderate SUI needed just a single IncontiLase® treatment. In total, 95% of all patients were incontinence free 12 months after the treatment, while 5% still had mild stress incontinence.

Stress urinary incontinence (SUI) is a common problem in women that causes the involuntary loss of urine during coughing, sneezing, laughing, or physical exertion such as running or climbing stairs.

Most adults can hold over 2 cups of urine in their bladder. Stress incontinence occurs when the muscles that control your ability to hold get weak or do not work.

• The bladder and urethra are supported by the pelvic floor muscles. Urine flows from your bladder through your urethra to the outside.
• The sphincter is a muscle around the opening of the bladder. It squeezes to prevent urine from leaking through the urethra.

When either set of muscles become weak, urine can pass when pressure is placed on your bladder. You may notice it when you:

• Cough
• Sneeze
• Laugh
• Exercise
• Lift heavy objects

“At the beginning I didn’t believe that such a simple treatment as IncontiLase could be so effective in treating indications such as mild and moderate Stress Urinary Incontinence. But when my first patient, whom I treated one year ago for moderate SUI, reported that she is dry from the day of the procedure, I began to change my mind. Today, after treating many patients, I can say that the results we have obtained with this new technology are exceeding my expectations. And after one year, my first patient is still dry and very happy with the change IncontiLase brought to her life.”

Novel minimally invasive laser treatment of urinary incontinence in women

Minimally invasive, non-ablative Er:YAG laser treatment of stress urinary incontinence in women – a pilot study

Treatment of female stress urinary incontinence with Erbium-YAG laser in non-ablative mode

Effects of laser procedure for female urodynamic stress incontinence on pad weight, urodynamics, and sexual function

Vaginal erbium laser: the second-generation thermotherapy for the genitourinary syndrome of menopause

Minimal Invasive Laser Treatment for Female Stress Urinary Incontinence

First assessment of short-term efficacy of Er:YAG laser treatment on stress urinary incontinence in women: prospective cohort study

Minimally invasive laser procedure for early stages of stress urinary incontinence (SUI)

Novel Minimally Invasive VSP Er:YAG Laser Treatments in Gynecology

Additional Resources: visit the Laser and Health Academy* website for additional information about medical laser treatments that can be performed with Fotona laser systems.

• Normal PAP smear within last 12 months
• Clear urine culture, no urinary tract infections (as could be caused of incontinence), no vaginal infections
• Not pregnant
• Not a heavy smoker
• Not a lifestyle with daily heavy lifting, Incontinence may return after treatment with heavy pressure
• Not morbidly obese BMI <33 is best as increased weight can limit success of treatment
• No condition with chronic cough, increase intra-abdominal pressure
• No menstrual bleeding at time of treatment
• In the case of Incontinence it is helpful to start Voiding diary 3 days before scheduled treatment (IncontiLase) to record incidence of incontinence and activity that preceded
• Having IUD in place is not a contraindication to treatment

You can leave immediately after the procedure and continue your daily routine. There may be some minimal sensitivity after the procedure and a transparent discharge for 2-3 days afterwards. Sexual intercourse is not recommended for 1 week after the procedure.

• No special aftercare of medication or special accessories are required
• There may be mild swelling +/- erythema in the vaginal canal, spotting or increased secretions
• Take care to prevent trauma to the treated area
• Abstain from sexual intercourse for 1 week after treatment
• Refrain from inserting tampons into the vagina for 4 weeks or one cycle
• Avoid activities that increase pressure on bladder and treatment areas for one month such as heavy lifting
• Record a voiding diary for 3 days before next treatment in one month (IncontiLase)
• Make an appointment for reassessment after 1 month, to assess for second treatment
• Prolonged periods of sustained exercise are not recommended for 2 weeks
• Possible scant amount of bleeding, report any excessive amount
• The patient should make an appointment to be seen in case of adverse or unexpected effects

Please view documents available here 

RenovaLase® is a unique and innovative, non-invasive 2940 nm Er:YAG laser therapy for the symptoms of vaginal atrophy. It is based on the non-ablative photothermal treatment of the vaginal canal. Clinical studies show that it is an efficient, easy-to-use, quick and safe procedure that eliminates the need for long-term estrogen administration.

The RenovaLase treatment is based on laser-induced, mild and controlled heating of the vaginal tissue, which stimulates angiogenesis, fibroblast activity, and new collagen formation without thermal or ablative damage. The final result is increased epithelial thickness as well as vascularization of the lamina propria, along with a reduction of symptoms such as dryness, itching, irritation and dyspareunia.

Vaginal relaxation syndrome (VRS) is defined as laxity of the vaginal wall. It can result in loss of friction and sexual satisfaction for both a woman and her partner. Vaginal atrophy refers to the thinning of the wall of the vagina that often occurs post menopause and is associated with dryness.

The most common cause of vaginal relaxation is overstretching of the vaginal wall during childbirth, which can increase with the number of births. Other causes are congenital connective tissue weakness and natural ageing. Vaginal atrophy normally occurs post menopause due to lack of estrogen.

Until now, effective results for VRS could only be achieved through invasive surgical treatments such as anterior and posterior vaginal plastic surgery. There are many post-operative complications associated with these procedures and a high degree of dissatisfaction with the results. The treatment options for atrophy due to menopause and typically involve hormone therapy.

“I’m especially thrilled with the positive results we’ve had when treating vaginal atrophy. The use of the FotonaSmooth® laser in this very common pathology has set a new standard of treatment for my practice. We are able to move away from long-term hormone replacement therapies that have received negative media attention and created concern in our patients, and toward laser light treatments that have the patient symptom-free for many months with no adverse complications.”

Efficacy of erbium:YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopause

Vaginal erbium laser: the second-generation thermotherapy for the genitourinary syndrome of menopause 

Vaginal Erbium Laser: the Second Generation Thermotherapy for the Genitourinary Syndrome of Menopause (GSM) in Breast Cancer Survivors. A preliminary report of a pilot study

Short-term effect of vaginal erbium laser on the genitourinary syndrome of menopause

Laser Treatment of Vaginal Atrophy in Post-menopause and Post-gynecological Cancer Patients 

Additional Resources: visit the Laser and Health Academy* website for additional information about medical laser treatments that can be performed with Fotona laser systems.

• Normal PAP smear within the last 12 months
• Clear urine culture, no urinary tract infections (as could be caused by incontinence), no vaginal infections
• Not pregnant
• Not a heavy smoker
• Not a lifestyle with daily heavy lifting, Incontinence may return after treatment with heavy pressure
• Not morbidly obese BMI <33 is best as increased weight can limit the success of treatment
• No condition with a chronic cough, increased intraabdominal pressure
• No menstrual bleeding at the time of treatment
• In the case of Incontinence, it is helpful to start Voiding diary 3 days before scheduled treatment (IncontiLase) to record incidence of incontinence and activity that preceded
• Having IUD in place is not a contraindication to treatment

You can leave immediately after the procedure and continue your daily routine. There may be some minimal sensitivity after the procedure and a transparent discharge for 2-3 days afterwards. Sexual intercourse is not recommended for 1 week after the procedure.

• No special aftercare of medication or special accessories are required
• There may be mild swelling +/- erythema in the vaginal canal, spotting or increased secretions
• Take care to prevent trauma to the treated area
• Abstain from sexual intercourse for 1 week after treatment
• Refrain from inserting tampons into the vagina for 4 weeks or one cycle
• Avoid activities that increase pressure on bladder and treatment areas for one month such as heavy lifting
• Record a voiding diary for 3 days before next treatment in one month (IncontiLase)
• Make an appointment for reassessment after 1 month, to assess for second treatment
• Prolonged periods of sustained exercise are not recommended for 2 weeks
• Possible scant amount of bleeding, report any excessive amount
• The patient should make an appointment to be seen in case of adverse or unexpected effects

IntimaLase® is a unique, patent-pending Er: YAG laser therapy for incision less, non-invasive photothermal tightening of the vaginal canal. Clinical studies have shown that IntimaLase is an efficient, easy-to-perform, and safe procedure.

The indication for IntimaLase is vaginal relaxation syndrome, which is the loss of the optimum structural form of the vagina. This condition is generally associated with overstretching of the vaginal canal during childbirth as well as with natural ageing.

• Fotona’s 2940 nm Er: YAG non-ablative laser with proprietary “Smooth-mode” technology thermally affects the vaginal tissue, stimulating collagen remodelling and the synthesis of new collagen fibres in the vaginal mucosa tissue and collagen-rich endopelvic fascia.
• The final result of collagen neogenesis and remodelling is the tightening of the vaginal canal.

What to expect?

Almost 70% of patients are dry after 120 days. 120 Days after Incontilase treatment 94% of patients reported improvement And 68% of all patients claimed to be free of SUI symptoms.

Improvement of SUI in all measured parameters.

No adverse events noted in any of the studies.

Incontilase treatments are simple and quick.

No anaesthesia is required.

You walk in and walk out and there is no complications or incisions.

The procedure in incision less and painless with no cutting, bleeding or downtime.

As a non-ablative, minimally invasive procedure with Er: YAG, IntimaLase™ also represents a safer, faster and more patient-friendly solution that avoids the undesirable complications present with other vaginal tightening methods.

Clinical results show a tightened vaginal canal, greater sexual satisfaction and significant improvement in a patients’ quality of life.

Usually, two sessions are recommended.

No special pre-op preparation or post-op precautions are necessary.

Patients can immediately return to their normal everyday activities.

The latest scientific results clearly show great improvements in vaginal tightness and sexual gratification.
95% assessed the change of their vaginal tightness as strongly or moderately improved after IntimaLase treatment.

Average shrinkage of vaginal canal after IntimaLase treatment was 17%.

High level of patient satisfaction (97%).

Clinical results prove that the fast and easy-to-perform IntimaLase treatment is an effective, non-invasive procedure with no undesired side effects or contraindications.

Women may seek vaginal rejuvenation for varying reasons, which may include one or a combination of the following:

• Restoring vaginal tightness and narrowness to a pre-birth state.
• Removing of excess stretched vaginal lining.
• Repairing damage from childbirth.
• Improving the amount and intensity of sensation during sexual intercourse.
• Boosting self-confidence.

For most patients, a single session was sufficient for a significant tightening of the vaginal canal. If needed, the treatment was repeated after one month. No special pre-op preparation or post-op precautions were necessary. Patients could immediately return to their normal everyday activities.

“Following a global evolution toward minimally-invasive and patient-friendly procedures, a new protocol for vaginal tightening “Intimalase” has been developed that can provide patient vaginal rejuvenation, avoiding undesirable complications that are present in more invasive treatment alternatives such as CO2 laser.”

You can leave immediately after the procedure and continue your daily routine. There may be some minimal sensitivity after the procedure and a transparent discharge for 2-3 days afterwards. Sexual intercourse is not recommended for 1 week after the procedure.

• Normal PAP smear within the last 12 months
• Clear urine culture, no urinary tract infections (as could be caused by incontinence), no vaginal infections
• Not pregnant
• Not a heavy smoker
• Not a lifestyle with daily heavy lifting, Incontinence may return after treatment with heavy pressure
• Not morbidly obese BMI <33 is best as increased weight can limit the success of treatment
• No condition with a chronic cough, increased intraabdominal pressure
• No menstrual bleeding at the time of treatment
• In the case of Incontinence, it is helpful to start Voiding diary 3 days before scheduled treatment (IncontiLase) to record incidence of incontinence and activity that preceded
• Having IUD in place is not a contraindication to treatment

• No special aftercare of medication or special accessories are required
• There may be mild swelling +/- erythema in the vaginal canal, spotting or increased secretions
• Take care to prevent trauma to the treated area
• Abstain from sexual intercourse for 1 week after treatment
• Refrain from inserting tampons into the vagina for 4 weeks or one cycle
• Avoid activities that increase pressure on bladder and treatment areas for one month such as heavy lifting
• Record a voiding diary for 3 days before next treatment in one month (IncontiLase)
• Make an appointment for reassessment after 1 month, to assess for second treatment
• Prolonged periods of sustained exercise are not recommended for 2 weeks
• Possible scant amount of bleeding, report any excessive amount
• The patient should make an appointment to be seen in case of adverse or unexpected effects